196 related articles for article (PubMed ID: 35154362)
1. Theta-Defensins to Counter COVID-19 as Furin Inhibitors:
Negahdaripour M; Rahbar MR; Mosalanejad Z; Gholami A
Comput Math Methods Med; 2022; 2022():9735626. PubMed ID: 35154362
[TBL] [Abstract][Full Text] [Related]
2. Why All the Fury over Furin?
Osman EEA; Rehemtulla A; Neamati N
J Med Chem; 2022 Feb; 65(4):2747-2784. PubMed ID: 34340303
[TBL] [Abstract][Full Text] [Related]
3. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
4. The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms.
Paiardi G; Richter S; Oreste P; Urbinati C; Rusnati M; Wade RC
J Biol Chem; 2022 Feb; 298(2):101507. PubMed ID: 34929169
[TBL] [Abstract][Full Text] [Related]
5. Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin.
Ertan-Bolelli T; Bolelli K; Elçi SD; Belen-Apak FB
Cardiovasc Drugs Ther; 2024 Jun; 38(3):425-432. PubMed ID: 36401727
[TBL] [Abstract][Full Text] [Related]
6. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
7.
Pandey AK; Verma S
Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
[TBL] [Abstract][Full Text] [Related]
8. Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence.
Vankadari N
J Phys Chem Lett; 2020 Aug; 11(16):6655-6663. PubMed ID: 32787225
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SARS-CoV-2 Infection by Human Defensin HNP1 and Retrocyclin RC-101.
Kudryashova E; Zani A; Vilmen G; Sharma A; Lu W; Yount JS; Kudryashov DS
J Mol Biol; 2022 Mar; 434(6):167225. PubMed ID: 34487793
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcal proteases exhibit the potential to activate the latent SARS-CoV-2 spike protein.
Mjokane N; Sabiu S; Folorunso OS; Gcilitshana OMN; Albertyn J; Pohl CH; Sebolai OM
J Infect Public Health; 2024 Feb; 17(2):263-270. PubMed ID: 38128410
[TBL] [Abstract][Full Text] [Related]
11. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
12.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
13. Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): In silico analysis.
Çakır B; Okuyan B; Şener G; Tunali-Akbay T
Eur J Pharmacol; 2021 Jan; 891():173781. PubMed ID: 33271151
[TBL] [Abstract][Full Text] [Related]
14. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
15. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.
Cheng YW; Chao TL; Li CL; Chiu MF; Kao HC; Wang SH; Pang YH; Lin CH; Tsai YM; Lee WH; Tao MH; Ho TC; Wu PY; Jang LT; Chen PJ; Chang SY; Yeh SH
Cell Rep; 2020 Oct; 33(2):108254. PubMed ID: 33007239
[TBL] [Abstract][Full Text] [Related]
16. Identification of Kukoamine A, Zeaxanthin, and Clexane as New Furin Inhibitors.
Zaragoza-Huesca D; Martínez-Cortés C; Banegas-Luna AJ; Pérez-Garrido A; Vegara-Meseguer JM; Peñas-Martínez J; Rodenas MC; Espín S; Pérez-Sánchez H; Martínez-Martínez I
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269938
[TBL] [Abstract][Full Text] [Related]
17. Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations.
Dhameliya TM; Nagar PR; Gajjar ND
Mol Divers; 2022 Oct; 26(5):2775-2792. PubMed ID: 35132518
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targets and Computational Approaches on Drug Development for COVID-19.
Shanmugam A; Muralidharan N; Velmurugan D; Gromiha MM
Curr Top Med Chem; 2020; 20(24):2210-2220. PubMed ID: 32648845
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
20. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
